EMT has frequently been observed in drug-resistant cancer cells in both preclinical models and clinical samples [2], including resistance to anti-EGFR therapy in lung cancer [3, 4], resistance to androgen-deprivation therapy in prostate cancer [5], and resistance to chemotherapy in breast cancer [6]. This evidence concerns the gene EGFR and breast carcinoma.